On Wednesday, Informatica Corporation (NASDAQ:INFA)’s shares declined -0.12% to $48.45.
Informatica Corporation (INFA), the world’s number one independent provider of data integration software, recently declared two executive appointments to further strengthen the leadership team. Ginna Raahauge has joined as senior vice president and chief information officer (CIO), reporting to Mike Berry, executive vice president and chief financial officer. Additionally, Jeff Moses will serve as senior vice president of Cloud Sales, reporting to Charles Race, executive vice president of Worldwide Field Operations.
Raahauge brings more than two decades of technology and business leadership experience to her role as CIO at Informatica. Her focus will be on building a world-class IT organization in addition to enhancing the Cloud services. Most recently, Raahauge was the senior vice president and CIO of Riverbed, where she was responsible for efficiently enabling growth by delivering enterprise technology platforms for new business models.
Informatica Corporation provides enterprise data integration software and services worldwide. Its enterprise data integration products comprise PowerCenter, PowerExchange, and Data Integration Hub, in addition to PowerCenter Express, an entry-level data integration and profiling edition for departments or small to mid-market business, and cloud data integration solutions.
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)’s shares gained 1.82% to $17.37.
Adaptimmune Therapeutics plc (ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, declared that the U.S. Food and Drug Administration (FDA) has accepted the Company`s investigational new drug (IND) application for autologous genetically modified T-cells expressing improved T cell receptors (TCRs) specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), and that the IND is now active.
The acceptance of this IND allows Adaptimmune to initiate an open label Phase I/II study designed to evaluate its wholly-owned MAGE-A10 T therapeutic candidate in NSCLC. Site initiation activities are now underway, and the Company anticipates that enrollment will start in 2015.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
At the end of Wednesday’s trade, FormFactor, Inc. (NASDAQ:FORM)‘s shares dipped -0.26% to $7.75.
FormFactor, Inc. (NASDAQ: FORM) will report financial results for its 2015 fiscal second quarter on Wednesday, July 29, 2015, at 1:30 p.m. Pacific Daylight Time. The public is invited to listen to a live webcast of FormFactor’s conference call on the Investors section of the company’s web site at www.formfactor.com. A telephone replay of the conference call will be accessible about two hours after the conclusion of the call.
FormFactor, Inc. designs, develops, manufactures, sells, and supports semiconductor probe card products and solutions worldwide. The company’s probe cards are used to perform wafer test, which is the testing of the semiconductor die or chips on the semiconductor wafer. Its probe cards are used to test DRAM chips, counting LPDDR2, LPDDR3, LPDDR4, DDR, DDR2, DDR3, DDR4, SDRAM, PSRAM, and graphic DRAM; NOR, PCM, and NAND flash memory chips; and system-on-chip (SoC) devices, such as serial data devices, chipsets, microprocessors, microcontrollers, graphic processors, mobile RF, and analog and mixed-signal devices.
El Pollo LoCo Holdings Inc (NASDAQ:LOCO), ended its Wednesday’s trading session with -3.51% loss, and closed at $19.22.
El Pollo Loco (LOCO), the nation’s leading fire-grilled chicken chain, declared the launch of their new line of $5 Pollo Bowl Combos. The four new Pollo Bowls are a fresh take on the popular Original Pollo Bowl(R) and feature El Pollo Loco’s famous citrus-marinated, fire-grilled chicken in the new Chicken & Shrimp, Mexican Caesar, Ranchero and Power bowl options.
El Pollo Loco Holdings, Inc., through its partner, El Pollo Loco, Inc., develops, franchises, licenses, and operates quick-service restaurants under the El Pollo Loco name in the United States. The company offers individual and family-sized chicken meals, Mexican-inspired entrees, sides, and, alternative proteins.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.